Tracon pharmaceuticals, inc. (TCON)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities
Net loss

-4,021

-3,936

-5,199

-6,326

-7,213

-7,756

-9,085

-9,754

-8,364

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-6,566

-7,147

-

-5,871

-8,297

-6,526

-11,047

-6,447

-2,921

-3,995

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation

267

297

315

416

596

623

674

664

706

796

797

795

806

744

539

943

857

742

672

427

247

Common stock issued for services

-

-

-

-

-

-

-

-

-

0

6

10

13

-

-

-

-

-

-

-

-

Depreciation and amortization

4

4

5

6

7

7

7

7

7

7

7

11

23

24

22

24

24

18

15

10

8

Noncash interest

46

52

59

62

61

63

63

67

79

87

87

86

94

119

132

136

135

94

91

106

126

Amortization of debt discount

16

18

20

22

21

22

21

24

27

31

30

29

27

23

25

26

26

19

18

26

34

Amortization of premium/discount on short-term investments

-

0

0

16

36

44

45

10

1

3

2

3

1

1

-1

-1

-2

-

-

-

-

Lease asset amortization and liability accretion, net

-3

-

-

-

2

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of preferred stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

65

Deferred rent

-

-

-

-

-

1

1

2

7

6

38

32

-16

-15

-13

-13

-12

0

-9

13

-8

Deferred revenue

-

-

-

-

-

0

0

0

-3,000

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-485

-388

-

-437

-203

-964

-968

-868

-909

-805

Changes in assets and liabilities:
Prepaid expenses and other assets

-139

-369

623

-425

-480

231

-226

192

-289

150

627

-312

-109

-86

-292

265

155

-1,063

-2,112

2,637

962

Accounts payable and accrued expenses

-979

-1,343

-1,276

-583

-219

-1,119

1,578

-73

3,756

308

-10

907

-429

-584

58

-2,000

323

2,365

611

2,326

842

Accrued compensation and related expenses

-761

299

119

223

-750

308

335

-912

239

169

229

164

-656

400

209

194

-378

190

270

247

-352

Net cash used in operating activities

-5,292

-4,243

-6,583

-5,773

-7,051

-8,126

-6,225

-10,177

-6,255

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-7,565

-

-5,043

-9,454

-6,668

-7,518

-3,533

-3,312

-4,800

Purchase of property and equipment

-

-

-

-

-

-

-

-

-

9

6

18

6

0

0

0

3

50

13

62

2

Purchases of available-for-sale short-term investments

-

0

0

0

4,980

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of available-for-sale short-term investments

-

-

-

-

-

-

-

-

-

-

0

5,995

2,999

-

5,220

2,137

1,445

-

-

-

-

Proceeds from the maturity of available-for-sale short-term investments

-

0

0

10,000

9,000

19,000

0

0

5,000

3,000

3,000

4,500

7,205

5,465

1,891

2,225

10,001

-

-

-

-

Net cash provided by investing activities

-

0

0

10,000

4,020

5,054

0

-18,923

5,000

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities
Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

4,200

-

-3,329

88

8,553

-335

-10,518

-62

-2

Proceeds from long-term debt

-

-

-

-

-

-

-

-

-

0

0

0

8,000

-

-

-

-

-

-

-

-

Repayment of long-term debt

700

-

-

-

-

0

0

7,520

800

0

0

0

8,850

-

-

-

-

0

0

8,753

1,177

Proceeds from sale of common stock and warrants, net of offering costs

-

-

-

-

-

-24

-27

1,348

35,159

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of common stock and warrants

-

-

-

-

-

-

-

-

-

-

2,610

0

1,000

-

-

-

-

-

-

-

-

Proceeds from sale of common stock, net of offering costs

3,720

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3

0

36,263

Costs paid in connection with sales of common stock

-

-

-

-

-

-

-

-

-

-

80

91

168

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock under equity plans

-

-

-

-

-

-

-

-

-

49

0

92

31

50

0

121

7

130

42

0

7

Payment of tax withholdings related to net share settlements of vested restricted stock awards

6

0

0

0

20

0

0

0

78

0

0

0

137

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

3,014

1,602

-700

24

-20

15

-16

1,041

34,281

-

-

-

-

-

-

-

-

-

-

-

-

Decrease in cash and cash equivalents

-2,278

-

-

-

-3,051

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-124

-

4,000

121

7

2,074

39

-753

35,093

Increase in cash and cash equivalents

-

-

-

-

-

-

-

-28,059

33,026

-

6,863

-6,220

-3,489

6,062

-4,372

-9,245

1,892

-5,779

-14,012

-4,127

30,291